EDIT vs RTX
Editas Medicine Inc (EDIT) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
EDIT currently screens at market cap $375.2M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the EDIT and RTX stock pages for the full models.
Not investment advice.